Dr. Chang graduated from the University of North Carolina School of Medicine at Chapel Hill in 1991. He works in Carrollton, TX and specializes in Internal Medicine.
Name / Title
Company / Classification
Phones & Addresses
Mr Yong Chang COO
Huston's Mergers & Acquisitions, LLC Interchange Minus. Telemarketing Philippines. Family Insurance. Catalyst Circle Call Centers. Internet Selling Services. Product Sales via Telephone. Web Design. Internet Marketing Services. Sales Lead Generation. Sales Organizations. Marketing Programs & Services. Marketing Consultants. Search Engine Optimization Services. Internet Services. Import Representatives. Export Management. Business Consultants. Telephone Answering Service. Financial Services. Insurance Services - Commercial. Insurance Services. Insurance Consultants. Financial Planning Consultants
4401 Northside Parkway, Suite 395, Atlanta, GA 30327 (404)5674380
Yong K. Chang Owner
Green Press Commercial Printing · Copies
1150 Connecticut Ave NW, Washington, DC 20036 1829 M St NW, Washington, DC 20036 1899 L St NW, Washington, DC 20036 (202)7853456
Yong H. Chang Vice-President
Golfdom Retail · Ret Sporting Goods/Bicycles Whol Sporting/Recreational Goods
8203 Watson St, McLean, VA 22102 PO Box 9025, Mc Lean, VA 22102 (703)6378847, (703)7908844
Jaye Viner - Gaithersburg MD, US Yong Chang - Gaithersburg MD, US Jennifer McDevitt - Gaithersburg MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
A61K 39/395
US Classification:
4241451, 4241581
Abstract:
Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two doses of an antibody which binds both IGF-I and/or IGF-II. The doses are separated by about a week, or by about three weeks, and each dose comprises an amount of antibody greater than about 0.5 mg kg of patient body mass and less than about 50 mg per kg of patient body mass.
- GAITHERSBURG MD, US Yong Chang - Gaithersburg MD, US Jennifer McDevitt - Gaithersburg MD, US
International Classification:
C07K 16/22
Abstract:
Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two doses of an antibody which binds both IGF-I and/or IGF-II. The doses are separated by about a week, or by about three weeks, and each dose comprises an amount of antibody greater than about 0.5 mg kg of patient body mass and less than about 50 mg per kg of patient body mass.